Followers | 55 |
Posts | 11251 |
Boards Moderated | 2 |
Alias Born | 04/25/2012 |
Tuesday, October 06, 2020 11:41:00 AM
NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today provides an update on its commercialization plans.
Dave Rosa, president and CEO, NeuroOne, says, "We are pleased to announce that we have received finished product from all of our vendors for the initial launch of the EVO Cortical Electrode (EVO) product line and will soon begin the final stages of assembling, packaging, labeling and sterilizing the product for our initial product launch. In cooperation with our distribution partner, Zimmer Biomet, the initial launch sites have been confirmed and we are optimistic the Company will have available product for sale in November. In addition, the Company will collect feedback from the launch sites with the intent of presenting at future trade shows and potentially publishing these results."
Rosa continues, "Applications for these electrodes are expected for recording brain activity in epilepsy patients as well as brain mapping in patients with brain tumors that require resection. Many companies have been working on commercializing hi-density electrodes for years and we are extremely proud to be the first to receive FDA clearance. As we establish the technology in the commercial marketplace, the Company remains committed to pursuing the development of additional products that offer therapeutic properties in addition to recording capabilities in order to take full advantage of the technology. To support those efforts, we are currently expanding our development team in an order to expedite development."
EVO Cortical Electrodes, intended for recording, monitoring and stimulating brain tissue for up to 30 days, may have the potential to change the landscape of neurosurgical procedures. The technology, utilizes sophisticated, automated manufacturing processes and offers several advantages including a thin-film lightweight design, high resolution capabilities, reduced immunological response—as demonstrated in pre-clinical studies—and the potential to be placed in a minimally invasive manner.
https://finance.yahoo.com/news/neuroone-medical-technologies-corporation-provides-120000358.html
Recent NMTC News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/16/2024 04:15:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 08:30:27 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2024 01:03:52 PM
- NeuroOne® Announces Breakthrough Case Completed with OneRF™ Ablation System at the University Hospitals in Cleveland • GlobeNewswire Inc. • 09/10/2024 01:00:00 PM
- NeuroOne® to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2024 10:23:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 03:43:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 03:36:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 03:26:56 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/30/2024 08:31:07 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/16/2024 08:30:40 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/14/2024 08:34:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:15:28 PM
- NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/14/2024 08:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 12:59:13 PM
- NeuroOne® to Report Third Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on August 14 • GlobeNewswire Inc. • 08/12/2024 03:30:00 PM
- NeuroOne® Announces $2.65 Million Equity Financing And $3.0 Million Credit Facility • GlobeNewswire Inc. • 08/05/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 06:38:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 06:31:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 06:16:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:49:49 PM
- NeuroOne® Announces First in Human Ablations Completed with OneRF™ Ablation System • GlobeNewswire Inc. • 06/25/2024 01:00:00 PM
- NeuroOne® Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation • GlobeNewswire Inc. • 06/20/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 07:34:41 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM